Companies › Frontera Therapeutics
2 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology; next expected readout May 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FT-003 Gene therapy for diabetic macular edema; delivers intraocular protein with durable therape | – | Phase 1 | Diabetic Macular Edema; Neovascular Age-related Macular Degeneration | May 2028 |
| FT-001 Subretinal AAV5-delivered RPE65 gene therapy | RPE65 | Phase 1 | Biallelic RPE65 Mutation-associated Retinal Dystrophy | Nov 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05916391 | FT-003 | Phase 1 | Diabetic Macular Edema | Ophthalmology | May 2028 |
| NCT06492863 | FT-003 | Phase 1 | Neovascular Age-related Macular Degeneration | Ophthalmology | Oct 2028 |
| NCT06492876 | FT-003 | Phase 1 | Diabetic Macular Edema | Ophthalmology | Nov 2028 |
| NCT05858983 | FT-001 | Phase 1 | Biallelic RPE65 Mutation-associated Retinal Dystrophy | Ophthalmology | Nov 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.